RNA-Binding Proteins Identified as New Class of Drug Target for Cancers, Including Triple Negative Breast Tumors

Research by University of California, San Diego, School of Medicine scientists has demonstrated how RNA-binding proteins may represent a new class of drug target for cancers, including triple-negative breast cancer, a particularly difficult-to-treat cancer that lacks most other molecular drug targets. Their studies indicated that targeting RBPs holds “great promise” as a minimally toxic and highly specific treatment approach against specific cancer subtypes.